个人简介

王海芸，同济大学生命科学与技术学院生物信息学系教授，同济大学名课优师。1998年毕业于中南大学湘雅医学院，获学士学位；2004年毕业于哈尔滨医科大学，获硕士学位；2009年毕业于同济大学，获博士学位；2012-2014年美国哈佛医学院Dana-Farber癌症研究所访问学者；2022-2023年意大利都灵大学分子生物技术中心访问学者。2004年任职于同济大学生命院至今，专注对肿瘤异质性分子特征和本质的理解，并基此利用多模态组学数据，深入探索肿瘤治疗异质性的分子机理，进而开展精准医疗研究。先后主持国家自然科学青年基金1项，面上项目3项，主持企业合作项目2项，作为骨干参与国家精准医学研究重点专项和重大科学计划项目等研究。发表SCI论文40余篇，其中以通讯／第一作者在Briefings in Bioinformatics、Bioinformatics、EBioMedicine、GigaScience、Plos Computational Biology、BMC Genomics等国际生物信息学期刊发表，合作工作在Cell、PNAS、Cancer Cell等国际期刊发表。近五年培养的研究生分别获得上海市优秀毕业生、同济大学优秀学位论文、同济大学优秀毕业生、国家奖学金获得者、校级奖学金获得者等荣誉称号。

研究领域

1、肿瘤异质性与精准联合用药研究 2、癌症新型生物标志物研究

癌症基因组学与生物信息学

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wu T#, Dai Y#, Xu Y, Zheng J, Chen S, Zhang Y, Tian P, Zheng X*, Wang H*. ExosomePurity: tumour purity deconvolution in serum exosomes based on miRNA signatures. Briefings in Bioinformatics. 2023 May 19;24(3):bbad119. Chen S#, Zheng J#, Zhang B, Tang X, Cun Y, Wu T, Xu Y, Ma T, Cheng J, Yu Z*, Wang H*. Identification and characterization of virus-encoded circular RNAs in host cells. Microb Genom. 2022 Jun;8(6):mgen000848. Huang X, Xu Y, Qian L, Zhao Q, Liu P, Lü J, Guo Y, Ma W, Wang G, Li S, Luo A, Yang X, Wang H*, Yu Z*. Evolution of gene expression signature in mammary gland stem cells from neonatal to old mice. Cell Death Dis. 2022 Apr 12;13(4):335. Xu Y, Zheng J, Cai Z, Li W, K?hler J, Dai Y, Cheng X, Wu T, Zhang F, Wang H*. Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers. Front Cell Dev Biol. 2021 Nov 12;9:773101. Zheng J, Wang H*. Pharmaco-omics data sheds light on therapy-oriented prospects of precision medicine. EBioMedicine. 2021 Aug;70:103493. Dai Y, Cao Y, K?hler J, Lu A, Xu S*, Wang H*. Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes. BMC Genomics. 2021 Jan 6;22(1):27. Cai Z#, Xue H#, Xu Y, K?hler J, Cheng X, Dai Y, Zheng J, Wang H*. Fcirc: A comprehensive pipeline for the exploration of fusion linear and circular RNAs. Gigascience. 2020 Jun 1;9(6):giaa054. Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M*, Barbacid M*. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. Luo A#, Xu Y#, Li S#, Bao J, Lü J, Ding N, Zhao Q, Fu Y, Liu F, Cho WC, Wei X*, Wang H*, Yu Z*. Cancer stem cell property and gene signature in bone-metastatic Breast Cancer cells. Int J Biol Sci. 2020 Jul 19;16(14):2580-2594。 Kim K*, Lane EA, Saftien A, Wang H, Xu Y, Wirtz-Peitz F, Perrimon N*. Drosophila as a model for studying cystic fibrosis pathophysiology of the gastrointestinal system. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10357-10367. Wang H*, Lv Q, Xu Y, Cai Z, Zheng J, Cheng X, Dai Y, J?nne P, Ambrogio C*, K?hler J*. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. EbioMedicine. 2019 Nov;49:106-117. Chen W, Wang J, Shi J, Yang X, Yang P, Wang N, Yang S, Xie T, Yang H, Zhang M, Wang H*, Fei J*. Longevity Effect of Liuwei Dihuang in Both Caenorhabditis Elegans and Aged Mice. Aging and Disease. 2019 Jun 1;10(3):578-591. Liu R#, Wang J#, Ukai M, Sewon K, Chen P, Suzuki Y, Wang H*, Aihara K*, Okada-Hatakeyama M*, Chen L*. Hunt for the tipping point during endocrine resistance process in breast cancer by dynamic network biomarkers. JMol Cell Biol. 2018 Nov 1. Ambrogio C*, K?hler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD*, J?nne PA*. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018 Feb 8;172(4):857-868.e15. Wang L*, Wang H, Song D, Xu M, Liebmen M*. New strategies for targeting drug combinations to overcome mutation-driven drug resistance. Seminars in Cancer Biology. 2017 Feb;42:44-51. Liu Y, Fei T, Zheng X, Brown M, Zhang P*, Liu X*, Wang H*. An integrative pharmacogenomic approach identifies two-drug combination therapies for personalized cancer medicine. Sci Rep. 2016, 26:6. Wang J, Lv Q, Li X, Liu Y, Liu K, Wang H*. Post-transcriptional and translational regulation modulates gene co-expression behavior in more synchronized pace to carry out molecular function in the cell. Gene. 2016, 587(2). Zhang N#, Wang H#, Fang Y, Wang J*, Zheng X*, Liu X*. Predicting anticancer drug responses using a dual-layer integrated cell line-drug network model. Plos Computational Biology. 2015 Sep 29;11(9). Wang H*#, Zheng X#, Fei T, Wang J, Li X, Liu Y, Zhang F. Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clin Transl Med. 2015 Dec;4(1):66. Wang H*, Meyer C, Fei T, Wang G, Zhang F*, Liu X. A systematic approach identifies FOXA1 as a key factor in the loss of epithelial traits during the epithelial-to-mesenchymal transition in lung cancer. BMC Genomics. 2013, 14: 680. Wang H*, Wang Q, Shen B and Li X*. Systematic investigation of global coordination among mRNA and protein in cellular society. BMC Genomics. 2010, 11:364. Wang H*#, Wang Q*#, Li X, Shen B, Ding M and Shen Z. Towards patterns tree of gene coexpression in eukaryotic species. Bioinformatics. 2008,24(11)：1367-1373.